Cowen Starts Janux Therapeutics (JANX) at Outperform

Cowen analyst Marc Frahm initiates coverage on Janux Therapeutics (NASDAQ: JANX) with a Outperform rating.

The analyst comments "Janux's TRACTr platform is generating differentiated masked bispecific antibodies. Lead candidate PSMA-TRACTr is a T cell engager recognizing PSMA with potential utility in mCRPC. IND-enabling studies are underway with an IND filing expected in H1:22. We view PSMA-TRACTr as having WW sales potential of ~$1.7B and expect shares to Outperform as PSMA-TRACTr and the broader pipeline mature."

For an analyst ratings summary and ratings history on Janux Therapeutics click here. For more ratings news on Janux Therapeutics click here.

Shares of Janux Therapeutics closed at $25.40 yesterday.

You May Also Be Interested In

• UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
• JPMorgan Upgrades YTL Power International (YTLP:MK) to Overweight
• The Honest Co. (HNST) PT Raised to $5.70 at Morgan Stanley, 'Diaper Pressure Continues'